sellWeak cluster of 510b5-1 plan
Daniel Menold sold $473k of CBAY
Vice President, Finance at CymaBay Therapeutics, Inc.. 21,497 shares at an average of $21.99, traded Dec 15, 2023, filed Dec 15, 2023.
Warning score
32Value
$473k
21,497 shares
Holdings after
0
-215% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +17Trade size$473k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001062993-23-022638, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 15, 2023 | MOption exercise Common Stock10b5-1 | +10,000 | $4.05 | $41k | 10,000 | Dec 15, 2023 |
| Dec 15, 2023 | SOpen-market sale Common Stock10b5-1 | -10,000 | $21.98 | $220k | 0 | Dec 15, 2023 |
| Dec 15, 2023 | MOption exercise Common Stock10b5-1 | +11,497 | $8.43 | $97k | 11,497 | Dec 15, 2023 |
| Dec 15, 2023 | SOpen-market sale Common Stock10b5-1 | -11,497 | $21.99 | $253k | 0 | Dec 15, 2023 |
| Dec 15, 2023 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 145,109 | Dec 15, 2023 |
| Dec 15, 2023 | MOption exercise Employee Stock Option (right to buy)derivative10b5-1 | -11,497 | $0.00 | $0 | 0 | Dec 15, 2023 |
Related signals
Other insiders at CymaBay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $192k 6,000 shares | -100% | |
| 37Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $436k 18,403 shares | -107% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $118k 5,000 shares | -100% | |
| 28Weak | CymaBay Therapeutics, Inc. | Daniel Menold Vice President, Finance | $236k 10,000 shares | -100% | |
| 26Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $143k 6,000 shares | -100% | |
| 33Weak | CymaBay Therapeutics, Inc. | Charles McWherter President of R&D | $243k 11,332 shares | -57% | |
| 25Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $110k 5,000 shares | -100% | |
| 25Weak | CymaBay Therapeutics, Inc. | Janet Dorling director | $120k 6,000 shares | -100% | |
| 40Moderate | CymaBay Therapeutics, Inc. | Sujal Shah Chief Executive Officer | $1.3M 64,865 shares | -28% | |
| 24Weak | CymaBay Therapeutics, Inc. | Paul T Quinlan General Counsel | $87k 5,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.